GSA Capital Partners LLP Takes $431,000 Position in RxSight, Inc. $RXST

GSA Capital Partners LLP bought a new stake in RxSight, Inc. (NASDAQ:RXST) during the 2nd quarter, Holdings Channel reports. The fund bought 89,512 shares of the company’s stock, valued at approximately $431,000.

A number of other hedge funds have also modified their holdings of the company. Millennium Management LLC lifted its holdings in RxSight by 130.6% during the third quarter. Millennium Management LLC now owns 2,193,062 shares of the company’s stock worth $19,716,000 after acquiring an additional 1,241,885 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in RxSight by 761.0% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company’s stock worth $6,969,000 after purchasing an additional 1,000,000 shares during the period. Bank of America Corp DE increased its holdings in RxSight by 406.0% during the 3rd quarter. Bank of America Corp DE now owns 722,435 shares of the company’s stock worth $6,495,000 after purchasing an additional 579,653 shares in the last quarter. UBS Group AG boosted its position in shares of RxSight by 183.0% during the third quarter. UBS Group AG now owns 735,170 shares of the company’s stock worth $6,609,000 after buying an additional 475,395 shares during the period. Finally, Nuveen LLC grew its holdings in shares of RxSight by 609.7% during the fourth quarter. Nuveen LLC now owns 531,730 shares of the company’s stock worth $5,541,000 after buying an additional 456,803 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on RXST shares. Stifel Nicolaus cut their price objective on shares of RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of RxSight in a research report on Tuesday, July 7th. Wall Street Zen raised RxSight from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company lowered their target price on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, May 7th. Finally, Jefferies Financial Group set a $6.50 target price on shares of RxSight in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, RxSight currently has a consensus rating of “Reduce” and an average target price of $8.37.

RxSight Stock Performance

NASDAQ:RXST opened at $6.25 on Friday. The stock has a fifty day moving average price of $5.65 and a 200-day moving average price of $6.45. The company has a market cap of $259.94 million, a price-to-earnings ratio of -5.53 and a beta of 1.13. RxSight, Inc. has a fifty-two week low of $4.48 and a fifty-two week high of $13.22.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. The business had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $32.55 million. Research analysts predict that RxSight, Inc. will post -1.01 EPS for the current fiscal year.

RxSight Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non?invasive post?operative adjustments. Using ultraviolet light, surgeons can fine?tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.